CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Roche Holding AG (Participation) - ROGz CFD

252.5
0.9%
Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon - Fri: 08:00 - 16:20

  • Summary
  • Historical Data
Trading сonditions
Spread 0.7
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.0136 %
Charges from full value of position ($-2.58)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.0136%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.008623 %
Charges from full value of position ($-1.64)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.008623%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency CHF
Margin 5.00%
Stock exchange Switzerland
Commission on trade 0%

Key Stats
Prev. Close 254.8
Open 253.7
1-Year Change 0.2%
Day's Range 251.8 - 253.7
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 12, 2024 254.8 1.6 0.63% 253.2 255.7 251.7
Dec 11, 2024 251.9 -1.0 -0.40% 252.9 256.0 250.7
Dec 10, 2024 248.8 -7.0 -2.74% 255.8 256.5 248.8
Dec 9, 2024 252.0 -4.4 -1.72% 256.4 258.0 252.0
Dec 6, 2024 256.4 0.5 0.20% 255.9 256.9 253.3
Dec 5, 2024 253.7 -0.5 -0.20% 254.2 255.5 253.6
Dec 4, 2024 248.7 -4.6 -1.82% 253.3 254.6 248.7
Dec 3, 2024 249.8 -4.9 -1.92% 254.7 256.1 249.8
Dec 2, 2024 251.9 -2.5 -0.98% 254.4 255.8 249.7
Nov 29, 2024 249.9 -2.3 -0.91% 252.2 254.9 249.9
Nov 28, 2024 253.5 2.1 0.84% 251.4 254.1 251.4
Nov 27, 2024 247.5 -4.3 -1.71% 251.8 253.2 247.5
Nov 26, 2024 248.8 -1.9 -0.76% 250.7 253.8 248.8
Nov 25, 2024 253.1 1.4 0.56% 251.7 254.8 251.5
Nov 22, 2024 253.8 3.4 1.36% 250.4 255.1 250.4
Nov 21, 2024 250.6 2.8 1.13% 247.8 251.2 247.7
Nov 20, 2024 244.4 -7.3 -2.90% 251.7 252.8 244.3
Nov 19, 2024 250.0 -4.9 -1.92% 254.9 255.0 248.5
Nov 18, 2024 252.3 -3.1 -1.21% 255.4 255.4 251.5
Nov 15, 2024 255.1 -1.4 -0.55% 256.5 258.0 252.4

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Roche Company profile

About Roche Holding AG

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Roche Holding AG revenues increased 8% to SF62.8B. Net income decreased 3% to SF13.93B. Revenues reflect Diagnostics segment increase of 29% to SF17.76B, Chugai segment increase of 20% to SF4.51B, Rest of Europe segment increase of 16% to SF11.38B, Rest of Asia segment increase of 13% to SF9.75B, Germany segment increase of 29% to SF4.29B.

Equity composition

3 April 2001, 100 for 1 stock split.

Industry: Pharmaceuticals (NEC)

Grenzacherstrasse 124
BASEL
BASEL-STADT 4058
CH

People also watch

BTC/USD

101,388.80 Price
+1.560% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,649.29 Price
-1.170% 1D Chg, %
Long position overnight fee -0.0125%
Short position overnight fee 0.0043%
Overnight fee time 22:00 (UTC)
Spread 0.30

ETH/USD

3,899.42 Price
+0.770% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.44 Price
+3.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01217

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading